NASDAQ:AVXL - Anavex Life Sciences Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.73 +0.03 (+1.11 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$2.73
Today's Range$2.61 - $2.74
52-Week Range$1.85 - $6.27
Volume12,163 shs
Average Volume247,448 shs
Market Capitalization$118.80 million
P/E Ratio-8.00
Dividend YieldN/A
Beta0.93

About Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences logoAnavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.

Receive AVXL News and Ratings via Email

Sign-up to receive the latest news and ratings for AVXL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AVXL
CUSIPN/A
Phone844-689-3939

Debt

Debt-to-Equity RatioN/A
Current Ratio7.57
Quick Ratio7.57

Price-To-Earnings

Trailing P/E Ratio-8.00
Forward P/E Ratio-6.66
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book5.46

Profitability

EPS (Most Recent Fiscal Year)($0.33)
Net Income$-13,460,000.00
Net MarginsN/A
Return on Equity-73.46%
Return on Assets-65.73%

Miscellaneous

Employees10
Outstanding Shares44,660,000

Anavex Life Sciences (NASDAQ:AVXL) Frequently Asked Questions

What is Anavex Life Sciences' stock symbol?

Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL."

How were Anavex Life Sciences' earnings last quarter?

Anavex Life Sciences (NASDAQ:AVXL) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.01. View Anavex Life Sciences' Earnings History.

When is Anavex Life Sciences' next earnings date?

Anavex Life Sciences is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Anavex Life Sciences.

What price target have analysts set for AVXL?

3 analysts have issued 12 month price objectives for Anavex Life Sciences' shares. Their predictions range from $6.00 to $7.00. On average, they anticipate Anavex Life Sciences' stock price to reach $6.6667 in the next twelve months. View Analyst Ratings for Anavex Life Sciences.

What are Wall Street analysts saying about Anavex Life Sciences stock?

Here are some recent quotes from research analysts about Anavex Life Sciences stock:
  • 1. According to Zacks Investment Research, "ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways. " (5/22/2018)
  • 2. Maxim Group analysts commented, "We have increased our therapeutic rate cut in our model to 90%, from 75% – taking our price target to $5, from $14, which is still substantially higher versus the current stock price – due to a combination of factors which include: ○ The trial was delayed (biomarkers) and will take time and money. While the company has $28M in capital today, we believe a lot more capital will be needed as the next phases of clinical development get underway, ○ When will we see meaningful clinical data that can convince both KOL’s and Industry experts that the company may have a drug? It will take time." (2/8/2018)

Who are some of Anavex Life Sciences' key competitors?

Who are Anavex Life Sciences' key executives?

Anavex Life Sciences' management team includes the folowing people:
  • Dr. Christopher U. Missling, Chairman, Pres, CEO & Sec. (Age 52)
  • Ms. Sandra Boenisch, Principal Financial Officer & Treasurer (Age 37)
  • Mr. Stephan Toutain, Sr. VP of Operations (Age 52)
  • Dr. Emmanuel O. Fadiran RPh, Ph.D., Sr. VP of Regulatory Affairs
  • Dr. Tasos Zografidis M.S., Ph.D., VP of Clinical Operations

Has Anavex Life Sciences been receiving favorable news coverage?

News coverage about AVXL stock has trended positive on Friday, according to Accern. Accern identifies negative and positive news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Anavex Life Sciences earned a daily sentiment score of 0.33 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 46.95 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Who are Anavex Life Sciences' major shareholders?

Anavex Life Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Park West Asset Management LLC (6.75%), Northern Trust Corp (1.01%) and Schwab Charles Investment Management Inc. (0.17%). View Institutional Ownership Trends for Anavex Life Sciences.

Which institutional investors are buying Anavex Life Sciences stock?

AVXL stock was purchased by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Northern Trust Corp and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Anavex Life Sciences.

How do I buy shares of Anavex Life Sciences?

Shares of AVXL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anavex Life Sciences' stock price today?

One share of AVXL stock can currently be purchased for approximately $2.73.

How big of a company is Anavex Life Sciences?

Anavex Life Sciences has a market capitalization of $118.80 million. The biotechnology company earns $-13,460,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Anavex Life Sciences employs 10 workers across the globe.

How can I contact Anavex Life Sciences?

Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 844-689-3939 or via email at [email protected]


MarketBeat Community Rating for Anavex Life Sciences (AVXL)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  214 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  320
MarketBeat's community ratings are surveys of what our community members think about Anavex Life Sciences and other stocks. Vote "Outperform" if you believe AVXL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVXL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Anavex Life Sciences (NASDAQ:AVXL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Anavex Life Sciences in the last 12 months. Their average twelve-month price target is $6.6667, suggesting that the stock has a possible upside of 144.20%. The high price target for AVXL is $7.00 and the low price target for AVXL is $6.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.6667$8.6667$10.00$15.00
Price Target Upside: 144.20% upside176.01% upside296.83% upside260.58% upside

Anavex Life Sciences (NASDAQ:AVXL) Consensus Price Target History

Price Target History for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018Noble FinancialSet Price TargetBuy$7.00HighView Rating Details
5/16/2018Maxim GroupInitiated CoverageBuy$5.00 ➝ $7.00HighView Rating Details
3/8/2018Roth CapitalInitiated CoverageBuy ➝ Buy$6.00HighView Rating Details
10/5/2016FBR & CoReiterated RatingOutperform$10.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Anavex Life Sciences (NASDAQ:AVXL) Earnings History and Estimates Chart

Earnings by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ:AVXL) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.41 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS

Anavex Life Sciences (NASDAQ AVXL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/6/2018        
5/10/2018Q2 2018($0.10)($0.1070)ViewN/AView Earnings Details
2/7/2018Q1 2018($0.09)ViewN/AView Earnings Details
12/11/2017Q4 2017($0.10)($0.12)ViewListenView Earnings Details
8/7/2017Q3 2017($0.09)($0.09)ViewN/AView Earnings Details
5/10/2017Q2 2017($0.09)($0.09)ViewN/AView Earnings Details
2/7/2017Q1 2017($0.0820)ViewN/AView Earnings Details
12/12/2016Q4 2016($0.08)($0.18)ViewN/AView Earnings Details
8/11/2016Q316($0.09)($0.06)ViewN/AView Earnings Details
5/11/2016Q2($0.16)($0.06)ViewN/AView Earnings Details
2/8/2016Q116($0.12)ViewN/AView Earnings Details
12/29/2015Q4 2015($0.54)ViewN/AView Earnings Details
8/17/2015Q3 2015($0.08)ViewN/AView Earnings Details
5/15/2015Q2 2015($0.12)ViewN/AView Earnings Details
2/18/2015Q1 2015($0.08)ViewN/AView Earnings Details
12/30/2014Q4 2014($0.96)ViewN/AView Earnings Details
8/13/2014Q3 2014($0.12)ViewN/AView Earnings Details
5/15/2014Q2 2014($0.12)ViewN/AView Earnings Details
2/14/2013Q1 2013($0.04)ViewN/AView Earnings Details
12/22/2011Q4 2011($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Anavex Life Sciences (NASDAQ:AVXL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Anavex Life Sciences (NASDAQ AVXL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 12.10%
Institutional Ownership Percentage: 23.00%
Insider Trading History for Anavex Life Sciences (NASDAQ:AVXL)
Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Anavex Life Sciences (NASDAQ AVXL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/7/2018Christopher U MisslingInsiderBuy1,360$2.92$3,971.20View SEC Filing  
3/5/2018Christopher U MisslingCEOBuy1,500$2.63$3,945.001,015,400View SEC Filing  
3/2/2018Christopher U MisslingCEOBuy1,650$2.41$3,976.501,013,900View SEC Filing  
10/24/2017Christopher U MisslingCEOBuy375$4.92$1,845.001,011,875View SEC Filing  
10/19/2017Christopher U MisslingInsiderBuy375$4.49$1,683.751,011,500View SEC Filing  
10/17/2017Christopher U MisslingInsiderBuy375$4.27$1,601.25View SEC Filing  
10/13/2017Christopher U MisslingInsiderBuy750$4.22$3,165.00View SEC Filing  
10/5/2017Christopher U MisslingInsiderBuy375$4.30$1,612.50View SEC Filing  
10/2/2017Christopher U MisslingInsiderBuy375$4.20$1,575.001,009,625View SEC Filing  
9/28/2017Christopher U MisslingInsiderBuy375$4.21$1,578.751,009,250View SEC Filing  
9/26/2017Christopher U MisslingInsiderBuy375$3.88$1,455.001,008,875View SEC Filing  
9/20/2017Christopher U MisslingInsiderBuy375$4.23$1,586.251,008,500View SEC Filing  
9/18/2017Christopher U MisslingInsiderBuy375$4.40$1,650.001,008,125View SEC Filing  
9/14/2017Christopher U MisslingInsiderBuy375$4.58$1,717.501,007,750View SEC Filing  
9/11/2017Christopher U MisslingInsiderBuy375$4.81$1,803.751,007,375View SEC Filing  
9/7/2017Christopher U MisslingInsiderBuy375$4.76$1,785.001,007,000View SEC Filing  
9/5/2017Christopher U MisslingInsiderBuy375$4.90$1,837.501,006,625View SEC Filing  
8/31/2017Christopher U MisslingInsiderBuy375$4.48$1,680.001,006,250View SEC Filing  
8/28/2017Christopher U MisslingInsiderBuy375$4.44$1,665.001,005,875View SEC Filing  
8/24/2017Christopher U MisslingInsiderBuy375$4.54$1,702.501,005,500View SEC Filing  
8/21/2017Christopher U MisslingInsiderBuy375$4.07$1,526.251,005,125View SEC Filing  
8/18/2017Christopher U MisslingInsiderBuy375$3.81$1,428.751,004,750View SEC Filing  
8/14/2017Christopher U MisslingInsiderBuy375$3.70$1,387.501,004,375View SEC Filing  
8/11/2017Christopher U MisslingInsiderBuy750$3.55$2,662.501,004,000View SEC Filing  
7/14/2015Christopher U MisslingCEOBuy1,000$0.52$520.00View SEC Filing  
7/13/2015Christopher U MisslingCEOBuy1,000$0.53$530.00View SEC Filing  
7/7/2015Christopher U MisslingCEOBuy2,000$0.49$980.00View SEC Filing  
7/1/2015Christopher U MisslingCEOBuy2,000$0.45$900.00View SEC Filing  
6/23/2015Christopher U MisslingCEOBuy1,000$0.47$470.00View SEC Filing  
6/22/2015Christopher U MisslingCEOBuy1,000$0.42$420.00View SEC Filing  
6/16/2015Christopher U MisslingCEOBuy1,000$0.44$440.00View SEC Filing  
6/15/2015Christopher U MisslingCEOBuy1,000$0.43$430.00View SEC Filing  
6/10/2015Christopher U MisslingCEOBuy1,000$0.36$360.00View SEC Filing  
6/8/2015Christopher U MisslingCEOBuy1,000$0.35$350.00View SEC Filing  
6/4/2015Christopher U MisslingCEOBuy1,000$0.37$370.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Anavex Life Sciences (NASDAQ AVXL) News Headlines

Source:
DateHeadline
-$0.11 Earnings Per Share Expected for Anavex Life Sciences (AVXL) This Quarter-$0.11 Earnings Per Share Expected for Anavex Life Sciences (AVXL) This Quarter
www.americanbankingnews.com - May 22 at 1:18 AM
Anavex Life Sciences (AVXL) Raised to Buy at Zacks Investment ResearchAnavex Life Sciences (AVXL) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - May 16 at 5:31 PM
Anavex Life Sciences (AVXL) Given a $7.00 Price Target by Noble Financial AnalystsAnavex Life Sciences (AVXL) Given a $7.00 Price Target by Noble Financial Analysts
www.americanbankingnews.com - May 16 at 3:41 PM
Anavex Life Sciences (AVXL) Coverage Initiated at Maxim GroupAnavex Life Sciences (AVXL) Coverage Initiated at Maxim Group
www.americanbankingnews.com - May 16 at 3:41 PM
Anavex Life Sciences Corps (AVXL) CEO Christopher Missling on Q1 2018 Results - Earnings Call TranscriptAnavex Life Sciences Corp's (AVXL) CEO Christopher Missling on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 11 at 4:51 PM
Anavex Life Sciences (AVXL) Releases Quarterly  Earnings Results, Misses Estimates By $0.01 EPSAnavex Life Sciences (AVXL) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 11 at 1:53 PM
Edited Transcript of AVXL earnings conference call or presentation 10-May-18 8:30pm GMTEdited Transcript of AVXL earnings conference call or presentation 10-May-18 8:30pm GMT
finance.yahoo.com - May 11 at 10:15 AM
Anavex Life Sciences: Fiscal 2Q Earnings SnapshotAnavex Life Sciences: Fiscal 2Q Earnings Snapshot
finance.yahoo.com - May 10 at 9:28 AM
Anavex Life Sciences Reports Fiscal Second Quarter 2018 Financial ResultsAnavex Life Sciences Reports Fiscal Second Quarter 2018 Financial Results
finance.yahoo.com - May 10 at 9:28 AM
Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018Anavex Life Sciences to Announce Fiscal Second Quarter 2018 Financial Results on Thursday, May 10, 2018
finance.yahoo.com - May 9 at 9:15 AM
 Analysts Anticipate Anavex Life Sciences (AVXL) Will Announce Earnings of -$0.10 Per Share Analysts Anticipate Anavex Life Sciences (AVXL) Will Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - May 4 at 3:53 PM
Anavex Life Sciences (AVXL) Raised to Hold at ValuEngineAnavex Life Sciences (AVXL) Raised to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:20 AM
Comparing Senomyx (SNMX) and Anavex Life Sciences (AVXL)Comparing Senomyx (SNMX) and Anavex Life Sciences (AVXL)
www.americanbankingnews.com - April 29 at 7:36 PM
Anavex Life Sciences (AVXL) Cut to Hold at Zacks Investment ResearchAnavex Life Sciences (AVXL) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 24 at 5:22 PM
Active-Investors: Wired News - Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinsons Disease DementiaActive-Investors: Wired News - Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson's Disease Dementia
www.finanznachrichten.de - April 19 at 9:32 AM
Wired News – Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson’s Disease DementiaWired News – Anavex Life Sciences To Commence Phase-2 Study of ANAVEX(R)2-73 in Parkinson’s Disease Dementia
finance.yahoo.com - April 19 at 9:32 AM
Anavex Life Sciences Corp. (AVXL) Expected to Post Earnings of -$0.10 Per ShareAnavex Life Sciences Corp. (AVXL) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 17 at 1:17 PM
Anavex Life Sciences (AVXL) Upgraded at Zacks Investment ResearchAnavex Life Sciences (AVXL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 10 at 8:28 AM
Edited Transcript of AVXL earnings conference call or presentation 7-Feb-18 9:30pm GMTEdited Transcript of AVXL earnings conference call or presentation 7-Feb-18 9:30pm GMT
finance.yahoo.com - April 1 at 9:19 AM
Zacks: Anavex Life Sciences Corp. (AVXL) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Anavex Life Sciences Corp. (AVXL) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 1 at 1:26 AM
Zacks: Analysts Anticipate Anavex Life Sciences Corp. (AVXL) Will Post Earnings of -$0.10 Per ShareZacks: Analysts Anticipate Anavex Life Sciences Corp. (AVXL) Will Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - March 31 at 3:14 PM
Anavex Life Sciences (AVXL) Downgraded by Zacks Investment ResearchAnavex Life Sciences (AVXL) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 23 at 6:07 PM
Anavex Life Sciences (AVXL) Lifted to Buy at Zacks Investment ResearchAnavex Life Sciences (AVXL) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 5:49 PM
Reviewing Medgenics (GNMX) and Anavex Life Sciences (AVXL)Reviewing Medgenics (GNMX) and Anavex Life Sciences (AVXL)
www.americanbankingnews.com - March 13 at 1:18 AM
Anavex Life Sciences to Present at the 30th Annual ROTH ConferenceAnavex Life Sciences to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 9 at 10:59 AM
Anavex Life Sciences (AVXL) Coverage Initiated by Analysts at Roth CapitalAnavex Life Sciences (AVXL) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - March 8 at 10:37 AM
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for ... - GlobeNewswire (press release)Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for ... - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:42 PM
Anavex Life Sciences Strengthens Management Team and Board of Directors - GlobeNewswire (press release)Anavex Life Sciences Strengthens Management Team and Board of Directors - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:42 PM
44 Biggest Movers From Yesterday | Benzinga - Benzinga44 Biggest Movers From Yesterday | Benzinga - Benzinga
www.benzinga.com - March 7 at 4:42 PM
Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference - GlobeNewswire (press release)
globenewswire.com - March 7 at 4:42 PM
Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)Anavex Life Sciences to Present New Preclinical Data at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics (ASENT)
finance.yahoo.com - March 7 at 9:49 AM
Anavex Life Sciences to Present at Cowen and Company 38th Annual Health Care ConferenceAnavex Life Sciences to Present at Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:34 AM
Anavex Life Sciences Strengthens Management Team and Board of DirectorsAnavex Life Sciences Strengthens Management Team and Board of Directors
finance.yahoo.com - March 5 at 10:22 AM
Anavex Life Sciences (AVXL) "Buy" Rating Reaffirmed at Noble FinancialAnavex Life Sciences' (AVXL) "Buy" Rating Reaffirmed at Noble Financial
www.americanbankingnews.com - February 21 at 8:16 PM
Sevion Therapeutics (SVON) & Anavex Life Sciences (AVXL) Head to Head ReviewSevion Therapeutics (SVON) & Anavex Life Sciences (AVXL) Head to Head Review
www.americanbankingnews.com - February 20 at 7:08 PM
Anavex Life Sciences (AVXL) PT Set at $5.00 by Maxim GroupAnavex Life Sciences (AVXL) PT Set at $5.00 by Maxim Group
www.americanbankingnews.com - February 18 at 5:54 PM
Anavex Life Sciences (AVXL) Presents At BIO CEO & Investor Conference - SlideshowAnavex Life Sciences (AVXL) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 14 at 3:26 PM
Anavexs (AVXL) CEO Christopher Missling on Q1 2018 Results ... - Seeking AlphaAnavex's (AVXL) CEO Christopher Missling on Q1 2018 Results ... - Seeking Alpha
seekingalpha.com - February 9 at 6:37 AM
Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)Anavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 9 at 6:37 AM
Maxim Group Analysts Give Anavex Life Sciences (AVXL) a $14.00 Price TargetMaxim Group Analysts Give Anavex Life Sciences (AVXL) a $14.00 Price Target
www.americanbankingnews.com - February 8 at 9:28 PM
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial ResultsAnavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results
finance.yahoo.com - February 8 at 3:24 PM
Anavex Life Sciences to Present at the 2018 BIO CEO & Investor ConferenceAnavex Life Sciences to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 3:24 PM
Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results - GlobeNewswire (press release)Anavex Life Sciences Provides Clinical Programs Update and Reports Fiscal First Quarter 2018 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 8 at 6:27 AM
Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical ... - GlobeNewswire (press release)Anavex Life Sciences to Announce Fiscal First Quarter 2018 Financial Results and Provide an Update on Clinical ... - GlobeNewswire (press release)
globenewswire.com - February 5 at 3:23 PM
Anavex And Alzheimers Disease At The Crossroads - Seeking AlphaAnavex And Alzheimer's Disease At The Crossroads - Seeking Alpha
seekingalpha.com - January 30 at 3:24 PM
Anavex Life Sciences to Present at the Noble Capital Markets 14th ... - GlobeNewswire (press release)Anavex Life Sciences to Present at the Noble Capital Markets 14th ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 3:27 PM
Anavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor ConferenceAnavex Life Sciences to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference
finance.yahoo.com - January 24 at 9:52 AM
Anavex Life Sciences Reports Potential Normalization of ... - GlobeNewswire (press release)Anavex Life Sciences Reports Potential Normalization of ... - GlobeNewswire (press release)
globenewswire.com - January 16 at 11:27 AM
Jazz Pharmaceuticals (JAZZ) vs. Anavex Life Sciences (AVXL) Head-To-Head ComparisonJazz Pharmaceuticals (JAZZ) vs. Anavex Life Sciences (AVXL) Head-To-Head Comparison
www.americanbankingnews.com - December 18 at 11:34 PM
Edited Transcript of AVXL earnings conference call or presentation 11-Dec-17 9:30pm GMTEdited Transcript of AVXL earnings conference call or presentation 11-Dec-17 9:30pm GMT
finance.yahoo.com - December 13 at 3:40 PM

SEC Filings

Anavex Life Sciences (NASDAQ:AVXL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Anavex Life Sciences (NASDAQ:AVXL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Anavex Life Sciences (NASDAQ AVXL) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.